A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Praliciguat ([14C]-IW-1973) Following a Single Oral Dose in Healthy Male Subjects

The primary objective is to characterize the pharmacokinetics (PK) of praliciguat and total radioactivity and to assess the elimination of total radioactivity from a single oral dose of [14C]-praliciguat.

开始日期2019-03-01

申办/合作机构

Cyclerion Therapeutics

NCT03499106 / Completed临床1期

An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of IW-1973

The primary objective of the study is to evaluate the effect of itraconazole (a potent cytochrome P450 isoenzyme [CYP]3A inhibitor) on the pharmacokinetics of IW-1973.

开始日期2018-04-12

申办/合作机构

Cyclerion Therapeutics

NCT03254485 / Completed临床2期

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 Over 12 Weeks in Patients With Heart Failure With Preserved Ejection Fraction

The objective of the CAPACITY-HFpEF study is to evaluate the safety and efficacy of IW-1973 compared with placebo when administered daily for approximately 12 weeks to patients with HFpEF. The study will evaluate the effect of oral IW-1973 on peak exercise capacity in patients with HFpEF, with or without permanent or persistent atrial fibrillation.

开始日期2017-11-07

申办/合作机构

Akebia Therapeutics, Inc.

[+1]

100 项与 Praliciguat 相关的临床结果

登录后查看更多信息

100 项与 Praliciguat 相关的转化医学

登录后查看更多信息

100 项与 Praliciguat 相关的专利（医药）

登录后查看更多信息

项与 Praliciguat 相关的文献（医药）

2023-06-01·Current cardiology reports

Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure.

Review

作者: Liang, Bo ; Liang, Wei-Lin

PURPOSE OF REVIEW:

This review sought to summarize the current emerging soluble guanylate cyclase activators and stimulators in patients with heart failure, both heart failure with reduced and preserved ejection fraction, to provide a reference for soluble guanylate cyclase activators and stimulators discovery.

RECENT FINDINGS:

Heart failure is a common disease with considerable morbidity, hospitalization, and mortality Soluble guanylate cyclase is a key enzyme in the nitric oxide signaling pathway and has attracted rapidly growing interest as a therapeutic target in heart failure. Currently, several soluble guanylate cyclase agonists are in clinical development. Cinaciguat and praliciguat have shown no clear clinical benefit in patients with heart failure in clinical trials. Riociguat increased the 6-min walk distance, cardiac index, and stroke volume index as well as decreased N-terminal pro-B-type natriuretic peptide. Although these populations cover nearly every range of ejection fractions, these were not clinical trials directly in patients with heart failure but were designed in patients with pulmonary hypertension. Vericiguat is recommended in the latest American guideline for patients with heart failure with reduced ejection fraction; however, it gets mixed results in patients with heart failure with preserved ejection fraction. To date, only vericiguat reduces the composite of death from cardiovascular causes or first hospitalization for heart failure in patients with heart failure with reduced ejection fraction and riociguat might improve clinical symptoms and quality of life in patients with heart failure, both heart failure with reduced and preserved ejection fraction. We need more exploration about soluble guanylate cyclase activators and stimulators in patients with heart failure.

2023-01-06·Circulation research

Praliciguat and Soluble Guanylate Cyclase Stimulators for Peripheral Artery Disease

Communications

作者: Kim-Shapiro, Daniel B. ; McDermott, Mary M. ; Ismaeel, Ahmed ; Kosmac, Kate

2023-01-06·Circulation research

Praliciguat Promotes Ischemic Leg Reperfusion in Leptin Receptor-Deficient Mice

Article

作者: Chapouly, Candice ; Reynaud, Annabel ; Cornuault, Lauriane ; Mohammedi, Kamel ; Couffinhal, Thierry ; Renault, Marie-Ange ; Gadeau, Alain-Pierre ; Buys, Emmanuel S. ; Foussard, Ninon ; Rouault, Paul

Background::

Lower-limb peripheral artery disease is one of the major complications of diabetes. Peripheral artery disease is associated with poor limb and cardiovascular prognoses, along with a dramatic decrease in life expectancy. Despite major medical advances in the treatment of diabetes, a substantial therapeutic gap remains in the peripheral artery disease population. Praliciguat is an orally available sGC (soluble guanylate cyclase) stimulator that has been reported both preclinically and in early stage clinical trials to have favorable effects in metabolic and hemodynamic outcomes, suggesting that it may have a potential beneficial effect in peripheral artery disease.

Methods::

We evaluated the effect of praliciguat on hind limb ischemia recovery in a mouse model of type 2 diabetes. Hind limb ischemia was induced in leptin receptor-deficient (Lepr db/db ) mice by ligation and excision of the left femoral artery. Praliciguat (10 mg/kg/day) was administered in the diet starting 3 days before surgery.

Results::

Twenty-eight days after surgery, ischemic foot perfusion and function parameters were better in praliciguat-treated mice than in vehicle controls. Improved ischemic foot perfusion was not associated with either improved traditional cardiovascular risk factors (ie, weight, glycemia) or increased angiogenesis. However, treatment with praliciguat significantly increased arteriole diameter, decreased ICAM1 (intercellular adhesion molecule 1) expression, and prevented the accumulation of oxidative proangiogenic and proinflammatory muscle fibers. While investigating the mechanism underlying the beneficial effects of praliciguat therapy, we found that praliciguat significantly downregulated Myh2 and Cxcl12 mRNA expression in cultured myoblasts and that conditioned medium form praliciguat-treated myoblast decreased ICAM1 mRNA expression in endothelial cells. These results suggest that praliciguat therapy may decrease ICAM1 expression in endothelial cells by downregulating Cxcl12 in myocytes.

Conclusions::

Our results demonstrated that praliciguat promotes blood flow recovery in the ischemic muscle of mice with type 2 diabetes, at least in part by increasing arteriole diameter and by downregulating ICAM1 expression.

项与 Praliciguat 相关的新闻（医药）

2024-09-12

·生物制药小编

拜耳弃子重获新生

近日，知名“变废为宝”的二手商Roivant携带着新公司Pulmovant亮相欧洲呼吸学会大会，新公司Pulmovant手握肺动脉高压药mosliciguat，是从拜耳处收购得来。 Roivant公司的战略一直以来是收购其他人不要的管线，再将其开发，此次交易也不例外，拜耳在2022年上半年放弃了处于I期临床的mosliciguat的开发，而如今Roivant以1400万美元的预付款从拜耳获得了mosliciguat的全球许可权，未来里程碑付款高达2.8亿美元，拜耳还有资格获得专利使用费。 sGC通路的开发历程 Mosliciguat，前称BAY 1237592，是一款吸入剂型可溶性鸟苷酸环化酶（sGC）激动剂，靶向的是一氧化氮（NO）-可溶性鸟苷酸环化酶（sGC）-环鸟苷酸（cGMP）途径。这是1998年诺奖获得者Ferid Murad等三位科学家首次发现的通路，这位美国三院院士的团队最初在研究爆炸物硝化甘油为何能够治疗心脏病。他们意外发现硝化甘油释放的一氧化氮会作为信号分子刺激sGC，进而产生cGMP舒张血管。具体而言，sGC本身是NO的受体，在接收到NO信号后，会发生构象变化，由静息状态转变为高活力激活状态，进而催化GTP生成cGMP。cGMP作为第二信使，能够激活下游的效应蛋白，如PKG（蛋白激酶G），从而调节多种生理过程，如血管舒张、神经信号传递、血小板凝集等。在肺动脉高压和一些心血管疾病中，sGC通路受到抑制，这导致血管紧缩。因此靶向NO/sGC/cGMP途径被广泛认为是治疗心血管疾病，包括慢性心力衰竭、肺动脉高压等疾病的重要靶标。值得一提的是，“伟哥”西地那非同样也是在这一机制背景下开发的药物（“伟哥”西地那非是一种PDE-5抑制剂，PDE-5能够降解cGMP，而抑制PDE-5有利于血管舒张），因此亲自参与“伟哥”临床的Ferid Murad可以说是“伟哥”之父。“伟哥”为代表的PDE-5抑制剂同样也可以用于肺动脉高压。 sGC激动剂药物的困境从药物机制来看，Mosliciguat并不是非常新颖的，毕竟已经有上市药物在先。 mosliciguat的老东家拜耳正是sGC激动剂领域的研发大牛，2013年首款在美上市sGC激动剂Riociguat（利奥西呱）就是由拜耳开发的，Mosliciguat这款后续开发的吸入剂型是拜耳在诸多sGC激动剂中的尝试之一。利奥西呱的劣势主要在于可替代性，是西地那非等PDE-5抑制剂的下位替代，临床实践中常常是患者对西地那非无反应才使用利奥西呱，而且虽然是同一通路的不同机制，但是不能一同使用，否则可能造成严重低血压。考虑到相比之下西地那非价格也不贵，这也难怪，在商业上，利奥西呱并不算太成功，半衰期短，价格贵，又要经常服用，市场起步还晚，市场渗透率自然相对较低，增长也相对比较缓慢。而事实上，后续业内的sGC激动剂迭代产品开发也不顺利。Cyclerion Therapeutics公司想要将praliciguat用于保留射血分数的心衰、糖尿病肾病，但是19年I期临床的概念验证就失败了。开发的另外一款分子Olinciguat在镰状细胞性贫血中的临床也宣告失败，Cyclerion Therapeutics后续打算开发中枢神经系统中的sGC激动剂Zagociguat和CY3018，不过也已经出售给了Tisento Therapeutics公司，Cyclerion Therapeutics现在是待价而沽，寻求股东价值最大化的状态。拜耳方面，vericiguat在2021年以心衰适应症上市，但市场并不看好这一药物的未来市场前景，疗效看起来似乎不如诺华的Entresto和阿斯利康的达格列净，普遍给出的较低销售额预测。 2022年H1拜耳放弃了mosliciguat的开发，其实纵向对比Riociguat，mosliciguat已经将原本12h但半衰期提升到40h了。但横向对比，合作伙伴默沙东的肺动脉高压新药Sotatercept机制完全不相同，服药间隔长，三周一支，虽然价格贵，年治疗费用能达到24.2万美元，但效果好，市场普遍看好Sotatercept未来该是个重磅炸弹。 2024年上半年放弃了runcaciguat用于慢性肾病的开发，转而投入药效和药动更优化的BAY3283142。和上述的开发途径相比，此次Roivant倒是另辟蹊径。 Roivant的算盘拜耳的出售固然有拜耳新CEO上任改革的缩影，Roivant的收购也有自己的算盘。此次Roivant表示观察到Mosliciguat能够使肺动脉高压患者的肺血管阻力（PVR）持续降低高达38%，降幅确实是史无前例的，但值得指出的是，Roivant选择的适应症是与间质性肺病（PH-ILD）相关的肺动脉高压，选择的是存在巨大未满足临床需求中的药物，而他们认为这一患者群体在欧美可能有20万人。如果确实存在这样的一个市场，那么Roivant在这场博弈中可能确实找准了位置，未来默沙东新药Sotatercept可能会取代利奥西呱的位置，实际可能会反映在Sotatercept放量后利奥西呱的销售额变化。 Mosliciguat在这一空白市场的开发，可能为这类sGC激动剂药物找到出路。参考来源： Friebe A, Kraehling JR, Russwurm M, Sandner P, Schmidtko A. The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting report. Naunyn Schmiedebergs Arch Pharmacol. 2023 Aug;396(8):1669-1686. doi: 10.1007/s00210-023-02484-8. Epub 2023 Apr 20. 周婷婷,刘潇.可溶性鸟苷酸环化酶刺激药的研究现状[J].中国临床药理学杂志,2023,39(21):3178-3182.DOI:10.13699/j.cnki.1001-6821.2023.21.029.

并购专利到期

2023-12-04

·BioSpace

Cyclerion Appoints Regina Graul, Ph.D., as President

– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion’s president, she will lead the organization and will work closely with, and report directly to, the board of directors. She will be responsible for creating, implementing, and executing strategy as well as building a uniquely talented cross-functional management team. With Graul’s arrival, transitional commitments under the asset purchase agreement with Tisento Therapeutics completed, and general expense reductions largely in place, founding chief executive officer Peter Hecht, Ph.D. has completed his transitional assignment. As a result, he is stepping away from an operational role at Cyclerion, effective immediately, and will continue to work with Dr. Graul and her team as a strategic consultant and board director going forward. “I am thrilled to be joining Cyclerion at this pivotal moment. The recent additions of Dina Katabi and Michael Higgins as board members and the evolution of Cyclerion’s board and management team provide a key inflection point to re-envision the company’s future,” said Dr. Graul. “As we evaluate our existing assets and identify external value-creating opportunities, cutting-edge innovation and addressing unmet patient needs will be central tenets. Together with our outstanding board of directors, I look forward to building Cyclerion’s capabilities for its next chapter to bring meaningful medicines to the patients who need them most.” “I am optimistic about the future of Cyclerion with Regina shepherding the company, a top-notch board of directors, promising existing assets, and a strategy for growth and evolution through external innovation,” said Dr. Hecht. “Having worked with Regina personally for years at Microbia, Ironwood, and Cyclerion, I can attest to her effective leadership style, savvy sense of strategy, and ability to identify and advance promising science. I look forward to working with her and the rest of the board as we build the next phase of the company and seek to make important progress on behalf of patients.” Regina most recently served as vice president, program executive at EQRx, where she led cross-functional development teams in oncology, using the latest in clinical innovation to create and deliver sustainable solutions. Previously, she served as olinciguat program lead at Cyclerion where she oversaw all aspects of olinciguat research and development. She began her industry career at Ironwood Pharmaceuticals (formerly Microbia Inc.) after completing a postdoctorate at MIT. She received her Ph.D. in synthetic organic chemistry from Rice University and her B.A. in chemistry from Saint Anselm College. About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases. Cyclerion acquired 10 percent equity ownership in Tisento Therapeutics as part of an asset sale agreement in which Tisento acquired the brain-penetrant soluble guanylate cyclase (sGC) stimulators zagociguat and CY3018 acquired from Cyclerion. Cyclerion’s current portfolio includes novel sGC stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia. Olinciguat is a vascular sGC stimulator that Cyclerion intends to out-license for cardiovascular diseases. Concurrently, Cyclerion is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. Forward Looking Statement Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should”, “positive”, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about pursuing collaborations, licenses, mergers, acquisitions and/or other targeted investments aimed at enhancing shareholder value. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, those under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 22, 2023 and in our Form 10-Q filed with the SEC on July 28, 2023, as well as our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Contacts Investor & Media Relations Phone: 857-327-8778 Email: IR@cyclerion.com

高管变更并购

2023-11-30

·GlobeNewswire-Health Care

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced the appointments of Dina Katabi, Ph.D., and Michael Higgins to its Board of Directors. “Dina and Michael bring a unique combination of leadership capabilities, operating experience, and vast cutting-edge scientific knowledge. Having a world-renowned innovator and a biopharma veteran join the board facilitates the transformation of Cyclerion as we look ahead to possible licenses, mergers, acquisitions and/or other targeted investments,” said Errol DeSouza, Ph.D., chairperson of Cyclerion Therapeutics. Dina Katabi, Ph.D., is the Thuan and Nicole Pham Professor of Electrical Engineering and Computer Science at the Massachusetts Institute of Technology (MIT), the director of MIT’s Center for Wireless Networks and Mobile Computing, and a member of the National Academy of Engineering, the National Academy of Sciences, and the American Academy of Arts and Sciences. She is also a recipient of the MacArthur Genius Award. Her research focuses on digital health, machine learning, and wireless and mobile technologies. Several start-ups have been spun out of Dr. Katabi's lab. She is the co-founder and president of Emerald Innovations, a health analytics company that specializes in digital health solutions for passive, contactless, in-home monitoring. She received her Ph.D. and M.S. in Computer Science from MIT and her B.S. from Damascus University. Michael Higgins is a serial entrepreneur who has helped launch and build numerous companies during his 30+ year career. Michael served as Voyager Therapeutics’ Interim Chief Executive Officer from June 2021 to March 2022. In this role he was able to stabilize and relaunch the company through the completion of three major business development deals, and the restructuring of the management team and research portfolio. Mr. Higgins was an entrepreneur-in-residence at Polaris Partners from 2015 to 2020 where he helped the founding team launch Camp4 Therapeutics. From 2003 through 2014 he served as Senior Vice President, Chief Operating Officer at Ironwood Pharmaceuticals Inc., evolving the company from its early days as a venture backed start-up to a fully integrated commercial organization. Mr. Higgins has been a long-time board member and board chair at other public and private companies. He is currently Chairman of the Board of Voyager Therapeutics as well as Pulmatrix Therapeutics. He also served as Audit Committee Chair at Voyager and has extensive compensation committee and governance committee experience. His financial expertise ranges from seed stage financing to IPOs, and beyond. He earned a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business at Dartmouth College. About Cyclerion TherapeuticsCyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases. Cyclerion acquired 10 percent equity ownership in Tisento Therapeutics as part of an asset sale agreement in which Tisento acquired the brain-penetrant soluble guanylate cyclase (sGC) stimulators zagociguat and CY3018 acquired from Cyclerion. Cyclerion’s current portfolio includes novel sGC stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia and is being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that Cyclerion intends to out-license for cardiovascular diseases. Concurrently, Cyclerion is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. Forward Looking StatementCertain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should”, “positive”, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about pursuing collaborations, licenses, mergers, acquisitions and/or other targeted investments aimed at enhancing shareholder value. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, those under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 22, 2023 and in our Form 10-Q filed with the SEC on July 28, 2023, as well as our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. ContactsInvestor & Media RelationsPhone: 857-327-8778Email: IR@cyclerion.com

高管变更并购

100 项与 Praliciguat 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11274	-	-	DB16300

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
射血分数保留型心力衰竭	临床2期	美国	Cyclerion Therapeutics	2017-11-07
射血分数保留型心力衰竭	临床2期	美国	Akebia Therapeutics, Inc.	2017-11-07
射血分数保留型心力衰竭	临床2期	加拿大	Akebia Therapeutics, Inc.	2017-11-07
射血分数保留型心力衰竭	临床2期	加拿大	Cyclerion Therapeutics	2017-11-07
糖尿病肾病	临床2期	美国	Ironwood Pharmaceuticals, Inc.	2017-10-24
2型糖尿病肾脏病	临床2期	美国	Cyclerion Therapeutics	2017-08-01
2型糖尿病肾脏病	临床2期	美国	Akebia Therapeutics, Inc.	2017-08-01
2型糖尿病	临床2期	美国	Cyclerion Therapeutics	2016-09-01
高血压	临床2期	美国	Cyclerion Therapeutics	2016-09-01
心血管疾病	临床2期	美国	Ironwood Pharmaceuticals, Inc.	2016-08-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03254485 (CAPACITY-HFpEF \| CAPACITY HFpEF, CTgov)	临床2期	射血分数保留型心力衰竭	196	Placebo Oral Tablet	憲範淵構衊構獵餘夢鑰(醖衊糧糧廠築鏇築獵範) = 膚蓋憲網壓蓋淵蓋構艱願選夢鏇鑰構夢觸鹽艱 (壓選襯遞鹹壓範憲獵繭, 製衊製齋齋築範鑰餘鹽 ~ 簾憲構夢鑰壓憲壓築糧) 更多	-	2022-09-15
NCT03217591 (CTgov)	临床2期	2型糖尿病 \| 2型糖尿病肾脏病	156	Placebo	廠構選製築餘鬱憲簾顧(憲築淵憲醖鏇製糧選窪) = 鬱製顧網選鏇鬱積鑰選範範鬱鏇醖構觸顧鑰壓 (糧醖餘顧廠鬱遞簾觸壓, 顧鬱餘鬱繭醖齋夢壓襯 ~ 糧構範艱膚積選鏇鏇顧) 更多	-	2022-09-15
NCT03217591 (Pubmed \| Clin J Am Soc Nephrol)	临床2期	糖尿病肾病	156	Placebo	製築製獵範糧餘憲襯獵(窪遞蓋遞齋鬱築齋鬱獵) = 壓鬱繭憲醖艱膚膚糧衊淵蓋構淵獵繭鏇築醖衊 (餘醖艱獵膚廠選窪鏇壓, -28 ~ 0.4)	-	2020-12-31
				Praliciguat 20 mg	製築製獵範糧餘憲襯獵(窪遞蓋遞齋鬱築齋鬱獵) = 製鬱範遞鑰餘糧夢鹹夢淵蓋構淵獵繭鏇築醖衊 (餘醖艱獵膚廠選窪鏇壓, -36 ~ -18) 更多
NCT03254485 (CAPACITY HFpEF, Pubmed \| J Coll Physicians Surg Pak) 人工标引	临床2期	射血分数保留型心力衰竭	181	Praliciguat	鏇鹽積醖齋餘糧鑰願窪(醖積衊蓋憲獵廠憲鏇窪) = There were more dizziness (9.9% vs 1.1%), hypotension (8.8% vs 0%), and headache (11% vs 6.7%) TEAEs with praliciguat compared with placebo. 糧簾壓積壓襯製襯觸製 (築蓋廠齋壓窪鬱襯窪觸 ) 更多	不佳	2020-10-20
				Placebo
ASN2020	临床2期	糖尿病肾病 eGFR \| UACR \| HbA1c ... 更多	156	Placebo	膚窪觸鑰範構夢鹽廠窪(選積窪糧簾繭製鹹廠構) = 鹽獵窪廠願觸夢醖蓋壓憲選壓襯鬱積網鏇築淵 (鹽醖襯憲顧壓範夢簾鹽, -27 ~ 0) 更多	-	2020-10-19
				Praliciguat 20 mg	膚窪觸鑰範構夢鹽廠窪(選積窪糧簾繭製鹹廠構) = 襯網淵簾構蓋製鑰獵範憲選壓襯鬱積網鏇築淵 (鹽醖襯憲顧壓範夢簾鹽, -36 ~ -18)
NCT03091920 (phase 2a trial, CTgov)	临床2期	2型糖尿病 \| 高血压	26	Placebo	構鑰餘顧製夢網願鹽衊(製廠鑰鑰衊獵夢壓窪網) = 遞膚膚夢製衊壓遞壓糧製醖壓獵構餘鬱鹹網窪 (構願膚憲選觸艱衊鑰遞, 餘艱餘觸鹹築顧鹹夢製 ~ 窪製簾鏇鬱鏇餘積獵鬱) 更多	-	2020-08-31
ADA2020	N/A	糖尿病肾病	156	Placebo	衊鏇鏇壓鏇窪淵網繭憲(遞積餘鏇網鑰廠簾鬱蓋) = 網鹹艱衊築築憲製鬱夢夢觸齋顧蓋觸夢膚簾醖 (製鏇壓廠鬱憲艱膚製膚, [ ~ 27, 0]) 更多	积极	2020-06-01
				Praliciguat 20 mg	衊鏇鏇壓鏇窪淵網繭憲(遞積餘鏇網鑰廠簾鬱蓋) = 糧範範膚積鹽遞齋範願夢觸齋顧蓋觸夢膚簾醖 (製鏇壓廠鬱憲艱膚製膚, [ ~ 36, to 18])
NCT02906579 (CTgov)	临床2期	2型糖尿病 \| 高血压	11	Placebo (Control)	艱鑰繭衊窪繭鏇選構淵(蓋獵選願糧顧蓋繭選醖) = 窪遞顧醖鬱遞網遞齋網觸膚鬱繭衊網範獵鬱鬱 (遞簾構鏇壓餘齋齋蓋憲, 獵淵築鬱壓蓋廠壓艱遞 ~ 襯窪鬱獵糧構積積製遞) 更多	-	2020-04-16
				IW-1973 (10 mg IW-1973)	艱鑰繭衊窪繭鏇選構淵(蓋獵選願糧顧蓋繭選醖) = 鏇選願獵鹽範網網積鬱觸膚鬱繭衊網範獵鬱鬱 (遞簾構鏇壓餘齋齋蓋憲, 築積願簾廠獵壓鏇鬱構 ~ 選鬱鹽願衊醖夢顧積艱) 更多
NCT03091920 (Pubmed \| Dan Med J \| Diabetologia) 人工标引	临床2期	2型糖尿病 \| 高血压	26	praliciguat	鑰鹹齋醖獵網願願築襯(襯襯窪夢構繭壓簾選繭) = 選憲繭餘鬱餘網觸觸鑰築艱鬱廠遞構鬱構鹽襯 (遞願遞選餘遞網窪網鏇 ) 更多	积极	2020-04-01
				Placebo	-
NCT03091920 (phase 2a trial, EASD2018)	临床2期	糖尿病 \| 高血压	26	Praliciguat 40 mg once daily	顧遞網鏇構觸鬱範醖構(襯憲構膚網築艱築衊範) = 糧選願繭築淵衊選壓窪築範淵醖鏇獵製齋廠鏇 (窪齋壓糧鹽築襯願顧壓, [-295 ~ 57]) 更多	积极	2018-10-04
				Praliciguat 20 mg twice daily for 7 days then 40 mg once daily	顧遞網鏇構觸鬱範醖構(襯憲構膚網築艱築衊範) = 築鹽鏇艱窪夢鹹簾糧齋築範淵醖鏇獵製齋廠鏇 (窪齋壓糧鹽築襯願顧壓, [-295 ~ 57]) 更多